Novartis Secures Milestone in Multiple Sclerosis Treatment
By Editor • September 1, 2026 • 1 min read
Novartis has achieved a significant breakthrough in treating multiple sclerosis with its BTK inhibitor, marking a promising development for patients.
In related news, Alumis reported disappointing results from its lupus treatment trial, while President Trump announced new drug pricing agreements with nine biotech firms.
Source: www.statnews.com
#Alumis #BTK inhibitor #drug pricing #lupus #multiple sclerosis #Novartis
